Vulnerable population. The University of Cincinnati (UC) Wellness implemented a buprenorphine for OUD in the

Vulnerable population. The University of Cincinnati (UC) Wellness implemented a buprenorphine for OUD in the ED protocol and evaluated outcomes. Description of Revolutionary Service: The buprenorphine for OUD inside the ED protocol was implemented in 2017. Individuals at risk for opioid withdrawal are assessed for baseline Clinical Opiate Withdrawal Scale (COWS) score. Individuals with baseline COWS score of 8 are treated with buprenorphine 4-8 mg. A starting dose of 8 mg is offered when baseline COWS scores 13. The COWS scores are reassessed at 45-60 minutes and p38γ review patients are re-dosed until a COWS , 8 is achieved. When reassessment COWS scores are , eight, the patient is discharged, if acceptable, with a naloxone prescription and buprenorphine-naloxone bridging therapy when needed. Referrals are created for outpatient therapy. Providers can administer buprenorphine for as much as 3 consecutive days even though establishing outpatient therapy. Impact on Patient Care/Institution: From June to December 2019, we evaluated 66 patients stratified into two groups depending on initial buprenorphine dose: 4 mg (n 21); eight mg (n 45). Baseline COWS score had been related involving groups [4 mg: ten (IQR: 8.5-14.5); 8 mg: 12.five (IQR: 9-16.five), P .34]. Thirty-one patients (47 ) had documented reassessment COWS; a comparable mean reduction in COWS score was observed irrespective of initial dose [4 mg: -7 (IQR: 2-10); eight mg: -9 (IQR: three.2-11.eight); P 44]. The 4 mg group demonstrated a longer ED length of stay [4.8 hours (IQR: three.5-6.three) versus three.9 hours (IQR: two.3-6.9); P 328]. On the 66 individuals evaluated, 16 (24.2 ) received a naloxoneMent Well being Clin [Internet]. 2021;11(two):75-172. DOI: 10.9740/mhc.2021.03.prescription at discharge. No adverse events attributed to buprenorphine were reported. Conclusion: Utilization of a greater beginning buprenorphine dose of eight mg was welltolerated and related using a reduction in ED length of remain.properly use naloxone (n 26, 33 ). Conclusion: Student pharmacist-led AD visits let for one-on-one, meaningful conversations on naloxone and opioid overdose education to take place. These visits can result in lowered stigma and barriers for pharmacists and market expanded access to naloxone for individuals and caregivers.Expanding Access to Naloxone With Student Pharmacists and Academic DetailingLauren Linder, PharmD, BCPS, BCPP1; Megan Pruitt, PharmD1; Elizabeth D. Weed, LISW-CP, PharmD, BCPP1; Talisha Ratliff, PharmDDepartment of Clinical Pharmacy and Outcomes Sciences, Health-related University of South Carolina (MUSC), Charleston, SC; two Presbyterian College College of Pharmacy, Clinton, SCImplementation of Pharmacy Solutions in Reaching Optimized Compliance to IPFQR Tobacco Use MeasuresMaggie Ramirez, PharmD, BCPSBryan Health, Lincoln, NEType: Revolutionary Practices. Background: Identifying and educating at-risk patients is really a recognized barrier for pharmacists dispensing naloxone. With the rise of opioid-related MMP-13 custom synthesis deaths in the course of the COVID-19 pandemic, there is an even greater have to have to address barriers and increase pharmacist expertise on naloxone and opioid overdose education. Coaching student pharmacists on academic detailing (AD) principles and opioid overdose education through pharmacy college rotations is an revolutionary approach to overcome barriers and expand access to naloxone. Description of Innovative Service: The service took place at two colleges of pharmacy in South Carolina (SC) with initial, second, and third year student pharmacists. Students attended two virtual coaching sessions hoste.